LLY · News · 20260823N
Product Launch - Foundayo
ELI LILLY & Co · 2026-08-23 · Importance 31 · Surprise 42 · In source text
Eli Lilly launched its once-daily oral weight-loss and type 2 diabetes pill Foundayo (orforglipron) in the United Kingdom, its first European market. The product is available through private prescriptions for adults with a body-mass index of at least 30, or 27 to 30 with a weight-related health condition. Foundayo is priced below Lilly’s Mounjaro injection, while Lilly is discussing potential NHS availability with NICE, broadening its prospective access beyond private-pay channels.
Key facts
- Eli Lilly has launched its oral weight-loss and type 2 diabetes pill, Foundayo (orforglipron), in the UK. source
- Foundayo (orforglipron) launch in the UK marks Eli Lilly's first European availability for the pill. source
- The Foundayo pill will be accessible via private prescription in the UK. source
- Eli Lilly is in discussions with the National Institute for Health and Care Excellence (NICE) for a potential rollout of Foundayo within the state-run National Health Service. source
- Eli Lilly priced Foundayo lower than Lilly's Mounjaro injection in the UK private market. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Eli Lilly has launched its oral weight-loss and type 2 diabetes pill, Foundayo (orforglipron), in the UK. |